Health Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Sponsors
BioMarkIQ Scientific Technologies Private Limited
BioMarkIQ Scientific Technologies Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: newly diagnosed lung cancer patients with confirmed tissue biopsy and CT scan and no treatment or surgery before enrollment. Inclusion criteria for cancer cohort
Exclusion criteria
Exclusion criteria: Pediatric lung cancer patients, patients with history of previous cancers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To identify the panel of most sensitive and specific biomarkers amongst the 12 candidate protein biomarkers that can yield a sensitivity of more than 90%. To assess the sensitivity, specificity, positive predictive value, negative predictive value, and area under the receiver operating characteristic curve (AUC-ROC) of the biomarker panel for lung cancer diagnosis. To compare the diagnostic performance of individual biomarkers within the shortlisted panel and compare them with the entire panel. Timepoint: At the baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the correlation between biomarker levels and tumor characteristics, such as tumor size, histological subtype, or stage of lung cancer.Timepoint: At the baseline | — |
Countries
India
Contacts
Public ContactDr Snahlata Singh
BioMarkIQ Scientific Technologies Private Limited
Outcome results
None listed